1. Home
  2. PBYI vs RFAI Comparison

PBYI vs RFAI Comparison

Compare PBYI & RFAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • RFAI
  • Stock Information
  • Founded
  • PBYI 2010
  • RFAI 2024
  • Country
  • PBYI United States
  • RFAI Singapore
  • Employees
  • PBYI N/A
  • RFAI N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • RFAI
  • Sector
  • PBYI Health Care
  • RFAI
  • Exchange
  • PBYI Nasdaq
  • RFAI NYSE
  • Market Cap
  • PBYI 138.4M
  • RFAI 156.9M
  • IPO Year
  • PBYI N/A
  • RFAI 2024
  • Fundamental
  • Price
  • PBYI $2.91
  • RFAI $10.48
  • Analyst Decision
  • PBYI Strong Buy
  • RFAI
  • Analyst Count
  • PBYI 1
  • RFAI 0
  • Target Price
  • PBYI $7.00
  • RFAI N/A
  • AVG Volume (30 Days)
  • PBYI 280.0K
  • RFAI 10.3K
  • Earning Date
  • PBYI 05-08-2025
  • RFAI 01-01-0001
  • Dividend Yield
  • PBYI N/A
  • RFAI N/A
  • EPS Growth
  • PBYI 143.51
  • RFAI N/A
  • EPS
  • PBYI 0.77
  • RFAI N/A
  • Revenue
  • PBYI $232,668,000.00
  • RFAI N/A
  • Revenue This Year
  • PBYI N/A
  • RFAI N/A
  • Revenue Next Year
  • PBYI N/A
  • RFAI N/A
  • P/E Ratio
  • PBYI $3.78
  • RFAI $45.55
  • Revenue Growth
  • PBYI 2.67
  • RFAI N/A
  • 52 Week Low
  • PBYI $2.23
  • RFAI $10.00
  • 52 Week High
  • PBYI $5.20
  • RFAI $10.50
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 44.50
  • RFAI N/A
  • Support Level
  • PBYI $2.88
  • RFAI N/A
  • Resistance Level
  • PBYI $3.14
  • RFAI N/A
  • Average True Range (ATR)
  • PBYI 0.16
  • RFAI 0.00
  • MACD
  • PBYI 0.00
  • RFAI 0.00
  • Stochastic Oscillator
  • PBYI 11.36
  • RFAI 0.00

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About RFAI RF ACQUISITION CORP II

RF Acquisition Corp II is a blank check company.

Share on Social Networks: